Linezolid Therapy of Vancomycin-Resistant Enterococcus faecium Experimental Endocarditis
Open Access
- 1 February 2001
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (2) , 621-623
- https://doi.org/10.1128/aac.45.2.621-623.2001
Abstract
We compared the activities of linezolid (25 mg/kg of body weight, administered intraperitoneally every 8 h) and of vancomycin (25 mg/kg of body weight, administered intraperitoneally every 8 h) in a rat model of vanA vancomycin-resistant Enterococcus faecium experimental endocarditis. Results were expressed as median log 10 CFU per gram of vegetation after 3 days of treatment. The median log 10 CFU per gram of vegetation was 10.1 among 7 untreated control animals, 10.2 among 9 vancomycin-treated animals, and 7.9 among 10 linezolid-treated animals. Linezolid treatment was more active ( P < 0.05) than vancomycin treatment or no treatment.Keywords
This publication has 12 references indexed in Scilit:
- Linezolid Therapy of Staphylococcus aureus Experimental OsteomyelitisAntimicrobial Agents and Chemotherapy, 2000
- Use of Linezolid, an Oxazolidinone, in the Treatment of Multidrug-Resistant Gram-Positive Bacterial InfectionsClinical Infectious Diseases, 2000
- Activities of the Oxazolidinones Linezolid and Eperezolid in Experimental Intra-Abdominal Abscess Due to Enterococcus faecalis or Vancomycin-Resistant Enterococcus faeciumAntimicrobial Agents and Chemotherapy, 1999
- The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faeciumJournal of Antimicrobial Chemotherapy, 1999
- In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant staphylococcus aureus and penicillin-resistant streptococcus pneumoniaeDiagnostic Microbiology and Infectious Disease, 1999
- Activity and Diffusion of LY333328 in Experimental Endocarditis Due to Vancomycin-Resistant Enterococcus faecalisAntimicrobial Agents and Chemotherapy, 1999
- Treatment of Endocarditis Due to Vancomycin‐ResistantEnterococcus faeciumwith Quinupristin/Dalfopristin, Doxycycline, and Rifampin: A Synergistic Drug CombinationClinical Infectious Diseases, 1998
- In Vitro Activity of LY333328 Against Vancomycin-Resistant Enterococci, Methicillin-Resistant Staphylococcus aureus, and Penicillin-Resistant Streptococcus pneumoniaeDiagnostic Microbiology and Infectious Disease, 1998
- Emergence of Increased Resistance to Quinupristin/ Dalfopristin During Therapy for Enterococcus faecium BacteremiaClinical Infectious Diseases, 1997
- Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococciAntimicrobial Agents and Chemotherapy, 1992